Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $64
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $67 to $64.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Moderna, PayPal And Some Other Big Gainers From Wednesday
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Recap Of Thursday’s Biotech Catalysts – End of The Day Summary
Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…
Oppenheimer Assumes Ionis Pharmaceuticals at Outperform, Announces Price Target of $59
Oppenheimer analyst Justin Kim assumes Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform rating and announces Price Target of $59.